Moxonidine is a second-generation centrally acting antihypertensive drug \[[Figure 1](#F1){ref-type="fig"}\].\[[@ref1]\] It has selective agonist activity at imidazoline I~1~ receptors and only minor activity at imidazoline α-2 adrenoceptors.\[[@ref2]\] Moxonidine reduce the activity of the sympathetic nervous system (SNS), because activates I~1~ imidazoline receptors in the rostal ventrolateral medulla (RVLM).\[[@ref3]\] The result is the inhibition of peripheral alpha-adrenergic tone, and the decrease of blood pressure, due to a fall in systemic vascular resistant.\[[@ref4]\] Moxinidine is used in patients with mild to moderate hypertension, as monotheraphy, or in combination with other antihypertensive agents.\[[@ref2][@ref5][@ref6]\] A plenty of studies demonstrate that moxonidine acts on heart, a target-organ. This effect is achieved through the activation of cardiac I~1~ imidazoline receptors.\[[@ref7]\] Through this mechanism, moxonidine produces clinically relevant sympatholysis, with beneficial effects on hemodynamics, coronary circulation, and neurohumoral parameters.\[[@ref8]\] Also, studies indicated that moxonidine has antiarrhythmic reaction,\[[@ref9]\] suppresses the activation of myocardial infarction, and reacts on postmyocardial infarction remodeling.\[[@ref10]\]

![Chemical structure of moxonidine](JPBS-5-253-g001){#F1}

Additional, moxonidine attenuates sympathetic tone\[[@ref11]\] and improves the hemodynamic profile in patients with congestive heart failure.\[[@ref12]\]

Also, moxonidine acts on other target-organs, like kidney and eye and on metabolism, with neutral or favorable effect on lipid parameters, improvement of insulin resistance in obese, and reduction of catecholamines. This may be due to the fact that moxonidine lowers leptin plasma levels and reduces weight in obese patients, through its action on SNS.\[[@ref13]\]

 {#sec1-1}

Influence of moxonidine on target-organ protection and metabolism {#sec2-1}
-----------------------------------------------------------------

During the last few years, a great number of studies involving moxonidine have been published. Most of them involve obesity, insulin resistance, and metabolic syndrome. Moxonidine reduces blood pressure in patients with metabolic syndrome while simultaneously reducing body weight in obese patients, as it has been showed in the postmarketing surveillance study CAMUS.\[[@ref14]\] Also, Chazova *et al*.,\[[@ref15]\] showed through a multicenter, prospective, randomized, open-label study that moxonidine improves insulin sensitivity in response to glucose challenge in patients with evidence of metabolic syndrome. This is the result of the reduction in plasma insulin levels. Moreover, several research groups independently found an improvement of insulin sensitivity in animals models too (mainly Zucker rats).\[[@ref16]\]

Sanjuliani *et al*.,\[[@ref17]\] showed that after 24 weeks of moxonidine treatment, plasma arterial adrenaline and noradrenaline were significantly reduced. This fact confirms the decrease of plasma catecholamines and, moreover, proves the action of the drug in conditions of sympathetic overactivity.

A double-blind, placebo-controlled crossover study demonstrate that moxonidine reduces exercise and mental stress-induced SNS activation and seems to be considered as an alternative to b-adrenoceptor blockers-in combination therapy-, when patients bothered by the exercise limitations of b-adrenoceptor blockers.\[[@ref18]\] This antihypertensive agent lowers intraocular pressure, suggesting a possible benefit in glaucoma.\[[@ref1]\]

The study of Krespi *et al*.,\[[@ref19]\] suggests that in hypertensive patients with microalbuminuria, moxonidine reduces urine albumin excretion, thrombomodulin, and Plasminogen activator inhibitor-1 (PAI-1) levels. These results demonstrate an effect on renal function and endothelial homeostatic mechanisms. Also, a 3-year trial showed that treatment with standard antihypertensive therapy and adjunctive moxonidine in patients with advanced renal failure was predicted to reduce the number of new end-stage renal disease cases compared to adjunctive nitrendipine. The model showed that adjunctive moxonidine seems to increase life-years lived.\[[@ref20]\]

Furthermore, moxonidine is used in the treatment of obese patients with metabolic syndrome, because this antihypertensive agent reduces leptin levels in plasma and reduces weight in obese patients, through the action of the SNS.\[[@ref13]\]

Effects of imidazoline receptor activation by moxonidine in heart function {#sec2-2}
--------------------------------------------------------------------------

A lot epidemiological studies have shown that increased activity of SNS leads to an increase in cardiovascular morbidity and mortality. Considering that moxonidine decrease the SNS activity, it is safe to administrate that the drug has a place in cardiovascular protection and reversal of metabolic disorders due to SNS overactivity.\[[@ref21]\]

Moxonidine is a selective imidazoline receptor (I~1~) agonist with central antihypertensive effects.\[[@ref1]\] Imidazoline I~1~ receptors have been localized in the brainstem RVLM, and in peripherical nervous system, including heart-mainly in cardiac atria.\[[@ref22]\] The atria are the primary site of atrial natriuretic peptide (ANP) production. The ANP is involved in blood pressure reduction and volume regulation.\[[@ref23]\] The chronic hypotensive effect of ANP is mediated by attenuation of cardiovascular sympathetic tone.\[[@ref24]\] Moxonidine can stimulate ANP release from heart.\[[@ref25]\] The increase in ANP may be explained in part by moxonidine SNS inhibition in heart.\[[@ref22]\]

A study, in spontaneously hypertensive rats, demonstrates that cardiac I~1~ receptors are upregulated and normalized by chronic antihypertensive treatment with moxonidine.\[[@ref26]\]

Also, an other study contends the acute hemodynamic effects of moxonidine. These are the reduction in right atrial pressure, pulmonary artery pressure, and cardiac index.\[[@ref27]\]

Additional, moxonidine seems to attenuate tachyarrhythmias\[[@ref28]\] and increase left ventricular ejection fraction, in patients with chronic heart failure.\[[@ref29]\] Also, moxonidine pretreatment provides a beneficial effect, during reperfusion-induced arrhythmias that appear after a brief period of myocardial ischemia.\[[@ref30]\]

Regarding moxonidine and heart, there are studies that support the chronic therapy with this agent, in patients with chronic heart failure.\[[@ref28]\] Chronic heart failure is associated with activation of SNS and the degree of this stimulation appears to be a marker for both the severity of the syndrome and the risk of death.\[[@ref31][@ref32][@ref33]\]

On the contrary, the MOXCON study (MOXonidine CONgestive Heart Failure) demonstrates that the use of moxonidine in patients with advanced heart failure was associated with an early increase in morbidity and mortality in a large cohort of New York Heart Association classes II-IV patient.\[[@ref34]\]

The use of moxonidine nowadays {#sec2-3}
------------------------------

Nowadays, according to the guidelines of ESH-ECS (European Society of Hypertension/European Society of Cardiology), moxonidine, as all centrally acting agents, is not a first-choice agent in antihypertensive treatment. It is mainly used in combination with the other categories of antihypertensive agents.\[[@ref35]\]

Also, overweight patients with metabolic syndrome are more likely to be on combination therapy. Despite good blood pressure response to moxonidine and more frequent use of combination therapy, less than 5% of diabetic patients achieve blood pressure target (\<130/80 mm Hg).\[[@ref14]\]

Furthermore, moxonidine should not be used as treatment in patients when glomerular filtration rate \< 30 ml/min.\[[@ref36]\]

Conclusion {#sec1-2}
==========

Moxonidine is the newest, second-generation, centrally acting antihypertensive agent. It is used in therapy of mild to moderate hypertension. Moxonidine has selective agonist activity at imidazoline I~1~ receptors and less adverse effects than the other centrally acting drugs. This fact authorizes the frequent use of moxonidine in clinical practice, as monotherapy or in combination with other antihypertensive agents. Also, the beneficial effects of moxonidine in target-organs, such as heart, are very important \[[Table 1](#T1){ref-type="table"}\]. Although, a lot of studies have conjecture the role that moxonidine displays in pathophysiological mechanisms, more studies are required, in order to clarify this role.
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